Trials / Recruiting
RecruitingNCT06493864
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumor
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open, multicenter, increasing dose and dose extension nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-B16D1 in patients with unresectable locally advanced or metastatic breast cancer and other solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-B16D1 | Administration by intravenous infusion for a cycle of 3 weeks. |
Timeline
- Start date
- 2024-08-26
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2024-07-10
- Last updated
- 2025-09-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06493864. Inclusion in this directory is not an endorsement.